Reboot Pain (tDCS) for Chronic Pain

This study is investigating if a non-drug brain stimulation treatment called Transcranial Direct Current Stimulation (tDCS) can help reduce chronic pain. tDCS uses a low electrical current to stimulate specific parts of the brain. The study is for adults aged 18-89 who are experiencing chronic pain and are already receiving mental health treatment through the Accelerated Behavioral Health Program (ABHP) at the Emory Healthcare Veterans Program (EHVP). To join, your pain intensity must be 4 or more for most of the day at least 3 days a week, and you must have a primary care provider or pain management provider. We are looking for 100 participants. The main goal is to see if tDCS improves your pain, enjoyment of life, and general activity, as measured by the PEG scale, by the end of the treatment period.

Study design
This is an interventional study planning to enroll 100 participants. It will test the effects of tDCS on chronic pain.
What's involved
You will receive daily tDCS treatment sessions, lasting about 20 minutes each, for two weeks. You will also complete daily pain surveys, questionnaires, and standard clinical interviews.
Compensation
Not stated in the trial record.
Follow-up
Your pain, enjoyment of life, and general activity will be measured at the start of the study and again 12 days after the treatment ends.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07411859

Reboot Pain (tDCS)

Recruiting
NAAges 18–89InterventionalTreatment
Emory University
~100 participants
Updated 2026-04-14 on ClinicalTrials.gov
What's tested:Transcranial Direct Current Stimulation

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in PEG (Pain, Enjoyment of Life and General Activity) scale
Measured over Baseline, day 12 post-intervention (end of treatment)
Chronic Pain
1 sites across 1 states
Georgia1
  • Sheila Rauch, PhD · PRINCIPAL_INVESTIGATOR · Emory University

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Male or Female, 18-89 years old
Treated on site for ABHP
Willing to self-administer tDCS and complete the measures
PEG pain intensity of 4 or more for most of the day at least 3 days per week
Have an established PCP (Primary Care Provider) or pain management provider

Exclusion

Implanted pacemaker
Seizure Disorder
Pregnancy, if applicable
Any new onset of the following:
Balance Problems
Difficulty walking
Bladder incontinence
Bowel incontinence
Numbness
Tingling
Weakness
Medical contraindications
Current use of sodium channel blockers
Lidocaine (OTC/transdermal delivery is ok)
Mexiletine
Amitriptyline; other tricyclic antidepressants
Anti-epileptic medications: phenytoin, carbamazepine, lamotrigine, oxcarbazepine, rufinamide, lacosamide and eslicarbazepine acetate
Current use of calcium channel blockers
Current use of N-Methyl-D-aspartate receptor antagonists
Ketamine
Dextromethorphan
Felbamate
History of brain surgery
History of brain tumor
History of seizure disorder
History of stroke
Intracranial metal implantation
Adults unable to consent
Individuals who are not yet adults
Prisoners
Non-English speaking
  • Change in PEG (Pain, Enjoyment of Life and General Activity) scaleBaseline, day 12 post-intervention (end of treatment)

    The PEG scale includes 3 questions each rated from 0 (no pain) to 10 (Pain as bad as you can imagine) over the past 24 hours. Items include average pain, interference in enjoyment, and interference in general activity. Higher score correlates with worse study outcome.